Kelyniam Global, Inc.

Kelyniam Global, Inc., a medical device manufacturing company, engages in the production of custom prosthetics utilizing computer aided design, and computer aided manufacturing of advanced medical grade polymers. The company develops, manufactures, and distributes custom cranial and craniofacial fixation screws for patients requiring the reconstruction of cranial and facial structures. It serves health systems, hospitals, sales representative, and surgeons, payors, and patients. The company was formerly known as Ketner Global Investments, Inc. and changed its name to Kelyniam Global, Inc. in December 2007. The company was incorporated in 2005 and is based in Collinsville, Connecticut.

Kelyniam Global, Inc. trades as KLYG on OTC. The company is classified in Healthcare / Medical - Devices and reports in USD.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $3.05M of revenue and -$138,555 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Kelyniam Global, Inc. can be compared against peers such as Algernon Pharmaceuticals Inc., Caduceus Software Systems Corp., Genix Pharmaceuticals Corporation, Imagion Biosystems Limited, Indo Global Exchange(s) PTE, Ltd., Medical Supply International USA, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $1.76M, beta of -0.06, and return on equity of -17.0%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

KLYG currently shows total debt of $508,818 and beta of -0.06. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: D (2024-12-09 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.kelyniam.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.